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SUMMARY 37 
Background: Newer-generation drug-eluting stents that combine ultrathin strut metallic platforms 38 
with biodegradable polymers might facilitate vascular healing and improve clinical outcomes in 39 
patients with acute myocardial infarction undergoing primary percutaneous coronary intervention 40 
(PCI) compared with contemporary thin strut second-generation drug-eluting stents. We did a 41 
randomised clinical trial to investigate the safety and efficacy of ultrathin strut biodegradable 42 
polymer sirolimus-eluting stents versus thin strut durable polymer everolimus-eluting stents in 43 
patients with acute ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI. 44 
 45 
Methods: The BIOSTEMI trial was an investigator-initiated, multicentre, prospective, single-blind, 46 
randomised superiority trial at ten hospitals in Switzerland. Patients aged 18 years or older with 47 
acute STEMI who were referred for primary PCI were eligible to participate. Patients were randomly 48 
allocated (1:1) to either biodegradable polymer sirolimus-eluting stents or durable polymer 49 
everolimus-eluting stents. Central randomisation was done based on a computer-generated 50 
allocation sequence with variable block sizes of 2, 4, and 6, which was stratified by centre, diabetes 51 
status, and presence or absence of multivessel coronary artery disease, and concealed using a 52 
secure web-based system. Patients and treating physicians were aware of group allocations, 53 
whereas outcome assessors were masked to the allocated stent. The experimental stent (Orsiro; 54 
Biotronik; Bülach, Switzerland) consisted of an ultrathin strut cobalt–chromium metallic stent 55 
platform releasing sirolimus from a biodegradable polymer. The control stent (Xience 56 
Xpedition/Alpine; Abbott Vascular, Abbott Park, IL, USA) consisted of a thin strut cobalt–chromium 57 
stent platform that releases everolimus from a durable polymer. The primary endpoint was target 58 
lesion failure, a composite of cardiac death, target vessel myocardial reinfarction (Q-wave and non-59 
Q-wave), and clinically-indicated target lesion revascularisation, within 12 months of the index 60 
procedure. All analyses were done with the individual participant as the unit of analysis and 61 
according to the intention-to-treat principle. The trial was registered with ClinicalTrials.gov, number 62 
NCT02579031. 63 
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Findings: Between April 26, 2016, and March 9, 2018, we randomly assigned 1300 patients (1623 64 
lesions) with acute myocardial infarction to treatment with biodegradable polymer sirolimus-eluting 65 
stents (649 patients and 816 lesions) or durable polymer everolimus-eluting stents (651 patients and 66 
806 lesions). At 12 months, follow-up data were available for 614 (95%) patients treated with 67 
biodegradable polymer sirolimus-eluting stents and 626 (96%) patients treated with durable 68 
polymer everolimus-eluting stents. The primary composite endpoint of target lesion failure occurred 69 
in 25 (4%) of 649 patients treated with biodegradable polymer sirolimus-eluting stents and 36 (6%) 70 
of 651 patients treated with durable polymer everolimus-eluting stents (difference –1·6 percentage 71 
points; rate ratio 0·59, 95% Bayesian credibility interval 0·37–0·94; posterior probability of 72 
superiority 0·986). Cardiac death, target vessel myocardial reinfarction, clinically-indicated target 73 
lesion revascularisation, and definite stent thrombosis were similar between the two treatment 74 
groups in the 12 months of follow-up. 75 
 76 
Interpretation: In patients with acute STEMI undergoing primary PCI, biodegradable polymer 77 
sirolimus-eluting stents were superior to durable polymer everolimus-eluting stents with respect to 78 
target lesion failure at 1 year. This difference was driven by reduced ischaemia-driven target lesion 79 
revascularisation in patients treated with biodegradable polymer sirolimus-eluting stents compared 80 
with durable polymer everolimus-eluting stents. 81 
 82 
Funding: Biotronik.  83 
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INTRODUCTION 84 
Primary percutaneous coronary intervention (PCI) is the preferred reperfusion strategy for patients 85 
with acute ST-segment elevation myocardial infarction (STEMI).1 Newer-generation drug-eluting 86 
stents have substantially improved clinical outcomes among patients with acute STEMI compared 87 
with bare-metal stents2 and early-generation durable polymer drug-eluting stents.3 88 
Biodegradable polymers and ultrathin stent platforms have been designed to mitigate inflammation 89 
and vascular injury, and to promote rapid endothelialisation in patients undergoing PCI. Newer-90 
generation drug-eluting stents that combine cobalt–chromium stent platforms with biodegradable 91 
polymers eluting sirolimus were found to be non-inferior4–6 or superior7 to contemporary durable 92 
polymer everolimus-eluting stents with respect to composite clinical endpoints at 1 year. Subgroup 93 
analyses from randomised trials suggested improved clinical outcomes in patients treated with 94 
biodegradable polymer drug-eluting stents compared with early-generation8 and newer-generation 95 
durable polymer drug-eluting stents.9 By contrast, subgroup analyses of patients with acute coronary 96 
syndromes enrolled into other randomised non-inferiority trials showed no difference in event 97 
numbers between patients treated with biodegradable polymer sirolimus-eluting stents and other 98 
newer-generation drug-eluting stents.5,6,10 99 
The prothrombotic and inflammatory milieu in patients with acute STEMI11 poses particular 100 
challenges to vascular healing12 and stent-related clinical outcomes13 after primary PCI and might 101 
reveal the differences among different stent platforms. However, to our knowledge, there are no 102 
dedicated randomised controlled trials comparing newer-generation drug-eluting stents in the 103 
setting of acute STEMI. Therefore, we did a randomised clinical trial to investigate the safety and 104 
efficacy of ultrathin strut biodegradable polymer sirolimus-eluting stents versus thin strut durable 105 
polymer everolimus-eluting stents in patients with acute STEMI undergoing primary PCI.  106 
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METHODS 107 
Study design and participants 108 
The BIOSTEMI trial was an investigator-initiated, multicentre, prospective, single-blind, randomised 109 
superiority trial that compared an ultrathin strut biodegradable polymer sirolimus-eluting stent with 110 
a thin strut durable polymer everolimus-eluting stent in patients with acute STEMI undergoing 111 
primary PCI at ten hospitals in Switzerland. The study rationale and design have been described 112 
previously.14 113 
Patients aged 18 years or older with acute STEMI who were referred for primary PCI within 24 h 114 
after symptom onset and with at least one culprit coronary lesion in one or more native target 115 
coronary vessels suitable for drug-eluting stent implantation were eligible to participate in the trial. 116 
Acute STEMI was defined as new persistent ST-segment elevation of 1 mm or greater in two or more 117 
contiguous leads, a new (or presumed new) left bundle branch block, or new (or presumed new) 118 
horizontal or down-sloping ST-segment depression of 1 mm or greater in leads V1–V3. Patients 119 
presenting with cardiogenic shock were eligible for inclusion. Patients with acute myocardial 120 
infarction due to stent thrombosis or those with mechanical complications were excluded. For full 121 
inclusion and exclusion criteria see the appendix (p 2). 122 
All conscious patients who were able to make an informed decision gave written informed consent 123 
for participation in the study before randomisation. Oral consent was accepted in conscious patients 124 
who were unable to read, interpret, and sign the informed consent form before intervention, but 125 
had to be confirmed as soon as possible after the intervention. Unconscious patients could be 126 
included with the consent of an independent physician not involved in the study that was called in to 127 
safeguard the interests of the patient. Consent by proxy had to be confirmed by the patient as soon 128 
as possible. In patients who revoked preliminary consent, data collected up to the time of 129 
withdrawal were anonymised and included in the analysis up to the time of revoked consent. 130 
The study protocol complied with the Declaration of Helsinki and was approved by the institutional 131 
ethics committees at each participating site. An academic steering committee designed the study. 132 
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The Clinical Trials Unit Bern (University of Bern, Switzerland) conducted the study and managed all 133 
study data. The trial statisticians did all analyses. 134 
 135 
Randomisation and masking 136 
Patients were randomly allocated (1:1) to either biodegradable polymer sirolimus-eluting stents or 137 
durable polymer everolimus-eluting stents. After successful crossing of the first target lesion with a 138 
coronary guidewire, central randomisation was done based on a computer-generated allocation 139 
sequence with variable block sizes of 2, 4, and 6, which was stratified by centre, diabetes status, and 140 
presence or absence of multivessel coronary artery disease, and concealed using a secure web-141 
based system. Patients and treating physicians were aware of group allocations, whereas outcome 142 
assessors were masked to the allocated stent. 143 
 144 
Procedures 145 
The experimental stent (Orsiro; Biotronik; Bülach, Switzerland) consists of an ultrathin strut (60 μm 146 
for stent diameters ≤3·0 mm and 80 μm for stent diameters >3·0 mm) cobalt–chromium metallic 147 
stent platform covered by an amorphous, hydrogen-rich, silicon-carbide passive layer, and an 148 
asymmetric biodegradable poly-Llactic acid polymer active coating that releases sirolimus at a dose 149 
of 1·4 μg per mm² stent surface over a period of 12–14 weeks.15 The control stent (Xience 150 
Xpedition/Alpine; Abbott Vascular, Abbott Park, IL, USA) consists of a thin strut (81 μm) cobalt–151 
chromium stent platform that releases everolimus from a durable poly-n-butylmethacrylate and 152 
vinylidine fluoride and hexafluoropropylene copolymer. 153 
Primary PCI was done in accordance with current guidelines at the time of enrolment. 154 
Intraprocedural medications included unfractionated heparin (5000 IU or 70–100 IU per kg of 155 
bodyweight) or bivalirudin. Glycoprotein IIb/IIIa inhibitors were administrated at the discretion of 156 
the operator. Dual antiplatelet therapy was started before or at the time of primary PCI and 157 
consisted of acetylsalicylic acid (loading dose 250–500 mg, maintenance dose 100 mg per day) in 158 
combination with preferably prasugrel (loading dose 60 mg; maintenance dose 10 mg per day) or 159 
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ticagrelor (loading dose 180 mg; maintenance dose 90 mg twice per day), or alternatively clopidogrel 160 
(loading dose 600 mg, maintenance dose 75 mg per day) for the recommended duration of 12 161 
months. There was no restriction with respect to the type or number of lesions treated. In patients 162 
with multivessel disease, revascularisation of all lesions in non-culprit vessels was done with uniform 163 
use of the randomly allocated study stent within the same procedure or during subsequent staged 164 
procedures, which were permitted within 3 months of the index procedure, at the investigator’s 165 
discretion. 166 
Clinical follow-up was done at 30 days by telephone interview to assess for adverse events. At 1 167 
year, patients underwent a physicial examination and a 12-lead electrocardiogram in an office visit. 168 
 169 
Outcomes 170 
The primary endpoint was target lesion failure, a composite of cardiac death, target vessel 171 
myocardial reinfarction (Q-wave and non-Q-wave), and clinically-indicated target lesion 172 
revascularisation, within 1 year of the index procedure. Secondary endpoints were all-cause death 173 
(cardiac and non-cardiac) at 30 days, 1 year, and 2 years; cardiac death at 30 days, 1 year, and 2 174 
years; myocardial infarction (Q-wave and non-Q-wave) at 30 days, 1 year, and 2 years; clinically-175 
indicated and not clinically-indicated target lesion revascularisation at 30 days, 1 year, and 2 years; 176 
clinically-indicated and not clinically-indicated target vessel revascularisation at 30 days, 1 year, and 177 
2 years; target vessel failure as a 178 
composite of cardiac death, any myocardial infarction, or any target vessel revascularisation at 30 179 
days, 1 year, and 2 years; definite stent thrombosis and definite or probable stent thrombosis at 30 180 
days, 1 year, and 2 years, and device, lesion, and procedural success. 2-year results are planned to 181 
be reported in a future publication. Analyses of all-cause death, cardiac death, target vessel 182 
myocardial infarction, definite stent thrombosis, and probable stent thrombosis were also done in 183 
the safety population, defined as all participants who received at least one biodegradable polymer 184 
sirolimus-eluting stent or one durable polymer everolimus-eluting stent. 185 
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Central and onsite data were monitored by the Clinical Trials Unit of the University of Bern. All 186 
participating sites received three onsite monitoring visits. Onsite monitors verified informed consent 187 
in all participants and checked key data in a random sample of 10% of enrolled patients at each 188 
participating site. Data were centrally monitored by the study statistician who checked each variable 189 
for entry, validity, consistency, and plausibility on an ongoing basis. An independent clinical events 190 
committee masked to treatment assignment adjudicated all study endpoints using standard 191 
definitions. The clinical events committee reviewed medical documentation, discharge summaries, 192 
and angiogaphy films if needed to assess safety and adverse events. 193 
 194 
Statistical analysis 195 
We used Bayesian statistical methods with robust priors incorporating historical data from 407 196 
patients with acute STEMI included in the BIOSCIENCE trial4 to assess the primary endpoint. 197 
We hypothesised that biodegradable polymer sirolimus- eluting stents were superior to durable 198 
polymer everolimus-eluting stents with respect to the primary composite endpoint of target lesion 199 
failure within 12 months of the index procedure. Based on the results of the acute STEMI subgroup 200 
analysis of the BIOSCIENCE trial,9 we assumed a rate ratio (RR) of the primary endpoint of 0·60, from 201 
7·0% with durable polymer everolimus-eluting stents to 4·2% with biodegradable polymer sirolimus-202 
eluting stents. The study protocol defined superiority of biodegradable polymer sirolimus-eluting 203 
stents over durable polymer everolimus-eluting stents if the posterior probability for an RR of less 204 
than 1 was greater than 0·975. 1250 patients were needed to show superiority of biodegradable 205 
polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents with 80% or 206 
greater power. All analyses were done with the individual participant as the unit of analysis and 207 
according to the intention-to-treat principle. Follow-up time was censored at the time of an event, 208 
loss to follow-up, or end of the planned follow-up, whichever occurred first. 209 
We used Bayesian log Poisson models incorporating historical data from the BIOSCIENCE trial.4 We 210 
estimated the log incidence rates in each of the two study groups for all clinical endpoints from the 211 
BIOSCIENCE trial (407 patients) with Bayesian log Poisson models with minimally informative priors 212 
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(μ=0, τ=0·111) and an offset term (log of the time at risk). Then, we used the posterior mean and SD 213 
of the log incidence rates in BIOSCIENCE as informative priors for the analysis of BIOSTEMI 214 
endpoints. For each endpoint, the robust prior was a 50:50 mixture between the historical 215 
informative prior (μ=posterior mean [BIOSCIENCE], τ=posterior SD [BIOSCIENCE]) and a vague prior 216 
(μ=0, τ=0·111) based on Bernoulli distributions. By use of Bayesian log Poisson models with time at 217 
risk fitted as an offset, we estimated the incidence in both study groups for all endpoints. The use of 218 
robust priors efficiently controlled the type I error rate by downweighting the contribution of 219 
historical information from the BIOSCIENCE trial if it turned out to be inconsistent with the 220 
information collected in the BIOSTEMI trial. RRs were reported as the median of the Bayesian 221 
posterior distribution and associated 95% Bayesian credibility intervals (CrIs) were reported as the 222 
2·5th and 97·5th percentiles of the Bayesian posterior distribution. Within the framework of this 223 
analysis, CrIs were interpreted similarly to CIs.16 224 
We did prespecified subgroup analyses according to diabetes and multivessel disease at baseline and 225 
post-hoc subgroup analyses according to age, sex, body-mass index, vessel diameter, lesion length, 226 
and renal failure. All subgroup analyses were done with the same approach as the main analyses. 227 
Specifically, robust historical priors were constructed by analysis of the primary endpoint in each 228 
subgroup of patients in the BIOSCIENCE trial with acute STEMI. These subgroup-specific robust 229 
historical priors were used to analyse the data from patients in the BIOSTEMI trial. For descriptive 230 
purposes, we derived Kaplan-Meier curves for patients included in the acute STEMI subgroup of the 231 
BIOSCIENCE trial and in the BIOSTEMI trial separately and combined. Full details including model 232 
equations and graphical representations of the priors are provided in the statistical analysis plan 233 
(appendix pp 94–121). 234 
Statistical analyses were done using R Studio version 3.5.2 and STATA version 15. The trial was 235 
registered with ClinicalTrials.gov, number NCT02579031. 236 
  237 
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Role of the funding source 238 
The funder of the study had no role in study design, data collection, data analysis, data 239 
interpretation, or writing of the report. DH, SW, JFI, OM, PJ, and TP had full access to all the data in 240 
the study and had final responsibility for the decision to submit for publication. 241 
 242 
RESULTS 243 
Between April 26, 2016, and March 9, 2018, we randomly assigned 1300 patients with acute STEMI 244 
and 1623 culprit lesions to treatment with biodegradable polymer sirolimus-eluting stents (649 245 
patients and 816 lesions) or durable polymer everolimus-eluting stents (651 patients and 806 246 
lesions; figure 1). At 1 year, follow-up data were available for 614 (95%) patients treated with 247 
biodegradable polymer sirolimus-eluting stents and 626 (96%) patients treated with durable 248 
polymer everolimus-eluting stents (figure 1). 249 
We summarised baseline clinical, angiographic, and procedural characteristics (tables 1, 2). 73 (11%) 250 
of 649 patients treated with biodegradable polymer sirolimus-eluting stents and 82 (13%) of 651 251 
patients treated with durable polymer everolimus-eluting stents presented with diabetes mellitus 252 
(table 1). Adherence to and type and duration of antiplatelet therapy were similar 253 
in the two treatment groups at 1 year (appendix pp 3–4). At 1 year, 175 (48%) staged procedures 254 
were done in the biodegradable polymer sirolimus-eluting stent group and 191 (52%) were done in 255 
the durable-polymer everolimus-eluting stent group. 256 
At 1 year of follow-up, the primary composite endpoint of target lesion failure occurred in 25 (4%) 257 
patients treated with biodegradable polymer sirolimus-eluting stents and in 36 (6%) patients treated 258 
with durable polymer everolimus-eluting stents (table 3). The prespecified criterion for superiority of 259 
ultrathin strut biodegradable polymer sirolimus-eluting stents compared with thin strut durable 260 
polymer everolimus-eluting stents was met (difference –1·6 percentage points; RR 0·59, 95% 261 
Bayesian CrI 0·37–0·94; posterior probability of superiority 0·986; figure 2). We observed little 262 
evidence for differences in cardiac death (18 [3%] vs 19 [3%]; difference –0·1 percentage points; RR 263 
0·77, 95% Bayesian CrI 0·43–1·40; posterior probability of superiority 0·806) and target vessel 264 
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myocardial reinfarction (5 [1%] vs 6 [1%]; difference –0·1 percentage points; 0·55, 0·19–1·60; 265 
posterior probability of superiority 0·875) between treatment groups. Clinically-indicated target 266 
lesion revascularisations were more frequent in the durable polymer everolimus-eluting stent group 267 
compared with the biodegradable polymer sirolimus-eluting stent group, but this difference was not 268 
significant (9 [1%] vs 17 [3%]; difference 1·2 percentage points; 0·55, 0·26–1·13; posterior probability 269 
of superiority 0·94; table 3; figure 3; appendix pp 8–9). We observed possible interactions for body-270 
mass index and renal failure for the primary endpoint, with posterior probabilities close to 0·975 271 
(figure 4). 272 
At 1 year, all-cause death occurred in 24 (4%) of 429 patients treated with biodegradable polymer 273 
sirolimus-eluting stents and in 22 (3%) of 651 patients treated with durable polymer everolimus-274 
eluting stents (table 3). Myocardial reinfarction occurred in 15 (2%) patients in the biodegradable 275 
polymer sirolimus-eluting stent group and in ten (2%) patients in the durable polymer everolimus-276 
eluting stent group, and target lesion revascularisation occurred in 11 (2%) patients treated with 277 
biodegradable polymer sirolimus-eluting stents and in 19 (3%) patients treated with durable polymer 278 
everolimus-eluting stents (table 3). 279 
At 12 months, definite stent thrombosis was documented in six (1%) patients treated with 280 
biodegradable polymer sirolimus-eluting stents and in eight (1%) patients treated with durable 281 
polymer everolimus-eluting stents (difference –0·3 percentage points; RR 0·68, 95% Bayesian CrI 282 
0·22–1·89; posterior probability of superiority 0·762; table 3). 283 
Clinical outcomes and Bayesian posterior probabilities with and without inclusion of historical 284 
information from the cohort of patients with acute STEMI in the BIOSCIENCE trial in the robust prior 285 
are provided in the appendix (pp 5–6). The RR of the primary endpoint of target lesion failure was 286 
0·69 (95% Bayesian CrI 0·41–1·15), with a posterior probability of superiority of 0·923, which 287 
increased to 0·986 after incorporation of historical information. 288 
In our analyses of the safety population, results for all-cause death, cardiac death, target-vessel 289 
myocardial infarction, definite stent thrombosis, and probable stent thrombosis were consistent 290 
with our primary analyses (appendix p 7). 291 
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DISCUSSION 292 
In this multicentre, randomised trial with a Bayesian design, we found that ultrathin strut 293 
biodegradable polymer sirolimus-eluting stents were superior to thin strut durable polymer 294 
everolimus-eluting stents with respect to the incidence of target lesion failure at 1 year of follow-up 295 
among patients with acute STEMI undergoing primary PCI. To our knowledge, the present study 296 
represents the first direct comparison between two newer-generation drug-eluting stents in patients 297 
with acute STEMI. 298 
Early-generation17,18 and newer-generation drug-eluting stents2 have progressively improved safety 299 
and efficacy outcomes compared with bare-metal stents in patients with acute STEMI undergoing 300 
primary PCI. Newer-generation drug-eluting stents that combine thin strut stent platforms with 301 
biocompatible durable polymer coatings were associated with further reductions in the risk of 302 
repeat revascularisation and stent thrombosis after primary PCI compared with early-generation 303 
thicker strut durable polymer drug-eluting stents.18 Newer-generation drug-eluting stents that 304 
combine thinner stent platforms with biodegradable or biocompatible polymer coatings have been 305 
introduced with the intent to further reduce thrombogenicity and vascular injury, accelerate 306 
endothelialisation, and potentially improve clinical outcomes.11 307 
In the present study, the difference in the primary endpoint between the two study groups was 308 
largely driven by fewer cases of clinically-indicated target lesion revascularisation in patients treated 309 
with biodegradable polymer sirolimus-eluting stents compared with durable polymer everolimus-310 
eluting stents. In the BIOFLOW-V trial,19 patients treated with biodegradable sirolimus-eluting 311 
stents were found to have fewer cases of ischaemia-driven target lesion revascularisation compared 312 
with patients treated with durable polymer everolimus-eluting stents at 2 years of follow-up. In the 313 
BIORESORT trial,5 which included 3514 patients, of whom almost a third presented with STEMI, the 314 
primary endpoint of target lesion failure was similar between patients treated with biodegradable 315 
polymer sirolimus-eluting stents, biodegradable polymer everolimus-eluting stents, and durable 316 
polymer zotarolimus-eluting stents at 1 year. Between 1 year and 2 years, target lesion 317 
revascularisations were significantly reduced in patients treated with biodegradable polymer 318 
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sirolimus-eluting stents compared with patients treated with durable polymer zotarolimus-eluting 319 
stents.20 Additionally, in patients with small vessel disease, target lesion revascularisation at 3 years 320 
was significantly lower in patients treated with biodegradable polymer sirolimus-eluting stents 321 
compared with biodegradable polymer everolimus-eluting stents and durable polymer zotarolimus-322 
eluting stents.21 In the BIONYX trial,6 durable polymer zotarolimus-eluting stents were non-inferior 323 
to biodegradable polymer sirolimus-eluting stents with no interaction regarding presentation with 324 
an acute coronary syndrome or stable coronary artery disease. 325 
The difference in the primary endpoint in our study was driven by clinically-indicated target lesion 326 
revascularisation. By contrast, the lower incidence of target lesion failure at 12-month follow-up 327 
reported in the BIOFLOW-V trial7 was driven by significantly fewer cases of target vessel myocardial 328 
infarction in patients treated with ultrathin strut biodegradable polymer sirolimus-eluting stents 329 
compared with thin strut durable polymer everolimus-eluting stents. The absence of a robust 330 
difference in the incidence of target vessel myocardial reinfarction between the two treatment 331 
groups in our study might be explained by the difficulty in detection of periprocedural myocardial 332 
reinfarction in the setting of acute STEMI.22 333 
The degradation time of the poly-L-lactic acid polymer used in the ultrathin strut sirolimus-eluting 334 
stent extends well beyond a year and might affect very late clinical outcomes. Additionally, the 335 
metallic stent platform composition, geometry, and strut thickness could affect clinical outcomes in 336 
patients with acute STEMI undergoing primary PCI. Ultrathin strut drug-eluting stents have been 337 
associated with a lower risk of target lesion failure and myocardial infarction compared with thin 338 
strut drug-eluting stents in a meta-analysis of randomised trials.23 A reduction in strut thickness has 339 
been shown to mitigate inflammation, vessel injury, neointimal proliferation, and thrombus 340 
formation.11,24,25 These findings are particularly relevant in the inflammatory milieu of acute STEMI 341 
and might explain the differences we observed in the incidence of target lesion failure and target 342 
lesion revascularisation in patients treated with biodegradable polymer sirolimus-eluting stents 343 
compared with those treated with durable polymer everolimus-eluting stents. The clinical benefit of 344 
biodegradable polymer sirolimus-eluting stents emerged within the first 12 months after drug-345 
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eluting stent implantation, well before complete degradation of the poly-L-lactic acid polymer and 346 
exposure to the passive silicon carbide coating previously shown to reduce thrombogenicity and 347 
facilitate endothelialisation.15 Minimisation of strut thickness might be an alternative strategy to 348 
completely biodegradable scaffolds, which have fallen short of expectations in randomised trials.26 349 
The pathophysiological correlate for a reduction in clinical events within the first year after stent 350 
implantation in patients treated with biodegradable polymer sirolimus-eluting stents compared with 351 
durable polymer everolimus-eluting stents warrants further study. Intravascular imaging studies and 352 
histopathological analysis might be needed to elucidate differences in the pattern of vascular 353 
inflammation and stent strut endothelialisation. 354 
In our analysis of the BIOSTEMI trial, we employed Bayesian methods to incorporate the results from 355 
the subgroup of patients with acute STEMI in the BIOSCIENCE trial (407 patients with acute STEMI 356 
representing 19% of the full BIOSCIENCE trial cohort) as prior information. This approach was 357 
prespecified and informed the power calculation of the BIOSTEMI trial, therefore allowing for 358 
increased efficiency by reducing the number of participants and trial duration. Compared with 359 
conventional meta-analyses, in which results from BIOSCIENCE and BIOSTEMI would be pooled using 360 
a fixed-effect meta-analysis, the use of robust priors in this approach efficiently controlled the type I 361 
error rate by downweighting the contribution of the historical information from the BIOSCIENCE trial 362 
if the historical information turned out to be inconsistent with the information collected in the 363 
BIOSTEMI trial. Accordingly, this approach strengthens the validity of our results. 364 
The results of the present study should be interpreted in view of several limitations. First, the trial 365 
was powered for superiority on the primary composite endpoint of target lesion failure using 366 
Bayesian methods and potential differences in individual clinical endpoints should be interpreted 367 
cautiously and are therefore hypothesis-generating. Likewise, the trial was not powered to examine 368 
differences in the individual endpoints contributing to the composite primary outcome. 369 
Nonetheless, treatment effects between this trial and the BIOSCIENCE subgroup with acute STEMI 370 
used as historical information in the robust prior were consistent, corroborating the robustness of 371 
our findings. Second, follow-up information was missing for 35 (5%) of 649 patients in the 372 
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biodegradable polymer sirolimus-eluting stent group and 25 (4%) of 651 patients in the durable 373 
polymer everolimus-eluting stent group because of refusal or loss to follow-up at 1 year. Our 374 
completeness of follow-up at 1 year was lower than in previous randomised trials of acute 375 
STEMI.27,28 Our study design allowed for provisional inclusion of patients on the basis of oral consent 376 
and for provisional inclusion of unconscious patients by consent by proxy. Although this approach 377 
might have facilitated the enrolment of an unselected patient population presenting with STEMI, it 378 
increased the number of patients who refused follow-up early after randomisation. Additionally, 379 
inclusion of patients with cardiogenic shock with high periprocedural risk might have diluted the 380 
expected difference between the two treatment groups. Third, beyond stent strut thickness and 381 
polymer characteristics, the study stents differ from each other in stent platform geometry, 382 
presence of a passive coating, the antiproliferative drug, drug load, and release kinetics. Therefore, 383 
the relative contribution of each individual stent component to the improved clinical outcomes 384 
observed among patients treated with ultrathin strut biodegradable polymer sirolimus-eluting stents 385 
compared with those treated with thin strut durable polymer everolimus-eluting stents cannot be 386 
definitively understood. Fourth, patients and treating physicians were not masked to treatment 387 
allocation. Fifth, we did not undertake post-procedural quantitative coronary angiography of the 388 
target lesion, nor was it mandatory to control the stent result using intracoronary imaging. Sixth, the 389 
clinical event committee relied on the information on clinical symptoms documented in the patient 390 
chart, which might have been biased by the judgment of the operator. Finally, the study was limited 391 
to one year of follow-up. Extended follow-up of previous trials in the setting of acute STEMI showed 392 
that the clinical benefits of newer-generation drug-eluting stents were maintained during long-term 393 
follow-up.29,30 The long-term effects of ultrathin strut biodegradable polymer sirolimus-eluting 394 
stents compared with thin strut durable polymer everolimus-eluting stents among patients with 395 
acute STEMI after degradation of the poly-L-lactic acid polymer therefore need evaluation during 396 
extended follow-up. 397 
In patients with acute STEMI undergoing primary PCI, ultrathin strut biodegradable polymer 398 
sirolimuseluting stents were superior to thin strut durable polymer everolimus-eluting stents with 399 
Published in final edited form as: Lancet. 2019 Oct 5;394(10205):1243-1253. doi: 10.1016/S0140-6736(19)31877-X 
respect to the primary endpoint of target lesion failure at 1 year. This difference was driven by fewer 400 
ischaemia-driven target lesion revascularisations in patients treated with biodegradable polymer 401 
sirolimus-eluting stents compared with patients treated with durable polymer everolimus-eluting 402 
stents. 403 
 404 
BOX: RESEARCH IN CONTEXT 405 
Evidence before this study 406 
In patients undergoing primary percutaneous coronary intervention (PCI) for acute myocardial 407 
infarction, randomised clinical trials have shown lower rates of the composite outcome of all-cause 408 
death, myocardial infarction, or revascularisation in patients treated with newer-generation drug-409 
eluting stents compared with bare-metal stents. We searched PubMed from inception up to June 30, 410 
2019, with no language restrictions, with the search terms “drug-eluting stent and acute myocardial 411 
infarction” and “drug-eluting stent and ST-segment elevation myocardial infarction”, and found no 412 
randomised head-to-head trials assessing the incremental benefit of different drug-eluting stents in 413 
patients with acute myocardial infarction. The available evidence shows favourable patient-oriented 414 
clinical outcomes in patients with myocardial infarction treated with newer-generation drug-eluting 415 
stents compared with bare-metal stents. 416 
 417 
Added value of this study 418 
To our knowledge, the BIOSTEMI trial is the first randomised comparison of two newer-generation 419 
drug-eluting stents in patients undergoing primary PCI for reperfusion therapy of acute myocardial 420 
infarction. The results of the present study showed fewer target lesion failures in patients treated 421 
with biodegradable polymer sirolimus-eluting stents compared with durable polymer everolimus-422 
eluting stents after 1 year of follow-up.  423 
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Implications of all the available evidence 424 
Although newer-generation drug-eluting stents are superior to bare-metal stents in patients 425 
undergoing primary PCI for acute myocardial infarction, refinements in stent technology combining 426 
ultrathin stent platforms with biodegradable polymers could further improve clinical outcomes. 427 
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DATA SHARING 468 
The BIOSTEMI trial is an investigator-initiated trial. Multiple substudies were predefined. Internal 469 
investigators who actively participated in the study and who provide a methodologically sound study 470 
proposal will be granted priority access to the study data for a period of 24 months. The study 471 
protocol underlying this paper will immediately be available with the published Article (appendix pp 472 
10–93). After 24 months, data underlying this manuscript plus relevant documentation will be made 473 
available to external investigators not affiliated to the trial whose proposed use of the data has been 474 
approved by an independent review committee identified by the steering committee for this 475 
purpose. Data will be deposited at https://boris.unibe.ch/132665/ where study proposals can also 476 
be filed. 477 
Published in final edited form as: Lancet. 2019 Oct 5;394(10205):1243-1253. doi: 10.1016/S0140-6736(19)31877-X 
ACKNOWLEDGMENTS 478 
The authors would like to thank Florim Cuculi, Stéphane Cook, and Alexios Karagiannis for their 479 
valuable contribution to the present study. This trial was supported by a dedicated research grant 480 
from Biotronik (Bülach, Switzerland). The steering committee (JFI, OM, EE, PJ, SW, and TP) and study 481 
statisticians (DH and SL) are solely responsible for the design and conduct of the study and all study 482 
analyses. The principal investigators (JFI, OM, and TP) vouch for the integrity and completeness of 483 
the study data and analyses and for the fidelity of this report to the study protocol and made the 484 
decision to submit the manuscript for publication. 485 
  486 
Published in final edited form as: Lancet. 2019 Oct 5;394(10205):1243-1253. doi: 10.1016/S0140-6736(19)31877-X 
REFERENCES 487 
1. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial 488 
infarction in patients presenting with ST-segment elevation: The Task Force for the management of 489 
acute myocardial infarction in patients presenting with ST-segment elevation of the European 490 
Society of Cardiology (ESC). Eur Heart J 2018; 39: 119–77. 491 
2. Piccolo R, Bonaa KH, Efthimiou O, et al. Drug-eluting or bare-metal stents for percutaneous 492 
coronary intervention: a systematic review and individual patient data meta-analysis of 493 
randomised clinical trials. Lancet 2019; 393: 2503–10. 494 
3. de Waha A, King LA, Stefanini GG, et al. Long-term outcomes of biodegradable versus durable 495 
polymer drug-eluting stents in patients with acute ST-segment elevation myocardial infarction: a 496 
pooled analysis of individual patient data from three randomised trials. EuroIntervention 2015; 10: 497 
1425–31. 498 
4. Pilgrim T, Heg D, Roffi M, et al. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus 499 
durable polymer everolimus-eluting stent for percutaneous coronary revascularisation 500 
(BIOSCIENCE): a randomised, single-blind, non-inferiority trial. Lancet 2014; 384: 2111–22. 501 
5. von Birgelen C, Kok MM, van der Heijden LC, et al. Very thin strut biodegradable polymer 502 
everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents 503 
in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority 504 
trial. Lancet 2016; 388: 2607–17. 505 
6. von Birgelen C, Zocca P, Buiten RA, et al. Thin composite wire strut, durable polymer-coated 506 
(Resolute Onyx) versus ultrathin cobalt–chromium strut, bioresorbable polymer-coated (Orsiro) 507 
drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-508 
blind, randomised non-inferiority trial. Lancet 2018; 392: 1235–45. 509 
7. Kandzari DE, Mauri L, Koolen JJ, et al. Ultrathin, bioresorbable polymer sirolimus-eluting stents 510 
versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary 511 
revascularisation (BIOFLOW V): a randomised trial. Lancet 2017;390: 1843–52. 512 
8. Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer 513 
versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a 514 
randomised non-inferiority trial. Lancet 2008; 372: 1163–73. 515 
9. Pilgrim T, Piccolo R, Heg D, et al. Biodegradable polymer sirolimus-eluting stents versus durable 516 
polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute 517 
myocardial infarction. EuroIntervention 2016; 12: e1343–54. 518 
10. Jensen LO, Thayssen P, Maeng M, et al. Randomised comparison of a biodegradable polymer 519 
ultrathin strut sirolimus-eluting stent with a biodegradable polymer biolimus-eluting stent in 520 
patients treated with percutaneous coronary intervention: the SORT OUT VII trial. Circ Cardiovasc 521 
Interv 2016; 9: e003610. 522 
11. Kolandaivelu K, Swaminathan R, Gibson WJ, et al. Stent thrombogenicity early in high-risk 523 
interventional settings is driven by stent design and deployment and protected by polymer-drug 524 
coatings. Circulation 2011; 123: 1400–09. 525 
12. Nakazawa G, Finn AV, Joner M, et al. Delayed arterial healing and increased late stent thrombosis 526 
at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an 527 
autopsy study. Circulation 2008; 118: 1138–45. 528 
13. Sarno G, Lagerqvist B, Nilsson J, et al. Stent thrombosis in new-generation drug-eluting stents in 529 
patients with STEMI undergoing primary PCI: a report from SCAAR. J Am Coll Cardiol 2014; 64: 16–530 
24. 531 
Published in final edited form as: Lancet. 2019 Oct 5;394(10205):1243-1253. doi: 10.1016/S0140-6736(19)31877-X 
14. Iglesias JF, Muller O, Zaugg S, et al. A comparison of an ultrathin-strut biodegradable polymer 532 
sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-533 
segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: 534 
rationale and design of the BIOSTEMI trial. EuroIntervention 2018; 14: 692–99. 535 
15. Iglesias JF, Roffi M, Degrauwe S, et al. Orsiro cobalt–chromium sirolimus-eluting stent: present and 536 
future perspectives. Expert Rev Med Devices 2017; 14: 773–88. 537 
16. Willink R, Lira I. A united interpretation of different uncertainty intervals. Measurement 2005; 38: 538 
61–66. 539 
17. Kalesan B, Pilgrim T, Heinimann K, et al. Comparison of drug-eluting stents with bare metal stents 540 
in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012; 33: 977–87. 541 
18. Bangalore S, Amoroso N, Fusaro M, Kumar S, Feit F. Outcomes with various drug-eluting or bare 542 
metal stents in patients with ST-segment-elevation myocardial infarction: a mixed treatment 543 
comparison analysis of trial level data from 34 068 patient-years of follow-up from randomized 544 
trials. Circ Cardiovasc Interv 2013;6: 378–90. 545 
19. Kandzari DE, Koolen JJ, Doros G, et al. Ultrathin bioresorbable polymer sirolimus-eluting stents 546 
versus thin durable polymer everolimus-eluting stents. J Am Coll Cardiol 2018; 72: 3287–97. 547 
20. Kok MM, Zocca P, Buiten RA, et al. Two-year clinical outcome of all-comers treated with three 548 
highly dissimilar contemporary coronary drug-eluting stents in the randomised BIO-RESORT trial. 549 
EuroIntervention 2018; 14: 915–23. 550 
21. Buiten RA, Ploumen EH, Zocca P, et al. Outcomes in patients treated with thin-strut, very thin-strut, 551 
or ultrathin-strut drug-eluting stents in small coronary vessels: a prespecified analysis of the 552 
randomized BIO-RESORT trial. JAMA Cardiol 2019; published online May 21. 553 
DOI:10.1001/jamacardio.2019.1776. 554 
22. Vranckx P, Cutlip DE, Mehran R, et al. Myocardial infarction adjudication in contemporary all-555 
comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions 556 
used in stent studies. EuroIntervention 2010; 5: 871–74. 557 
23. Bangalore S, Toklu B, Patel N, Feit F, Stone GW. Newer-generation ultrathin strut drug-eluting 558 
stents versus older second-generation thicker strut drug-eluting stents for coronary artery disease. 559 
Circulation 2018; 138: 2216–26. 560 
24. Kastrati A, Mehilli J, Dirschinger J, et al. Intracoronary stenting and angiographic results: strut 561 
thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 2001; 103: 2816–21. 562 
25. Pache J, Kastrati A, Mehilli J, et al. Intracoronary stenting and angiographic results: strut thickness 563 
effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol 2003; 41: 1283–88. 564 
26. Ali ZA, Serruys PW, Kimura T, et al. 2-year outcomes with the Absorb bioresorbable scaffold for 565 
treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised 566 
trials with an individual patient data substudy. Lancet 2017; 390: 760–72. 567 
27. Sabate M, Cequier A, Iñiguez A, et al. Everolimus-eluting stent versus bare-metal stent in ST-568 
segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled 569 
trial. Lancet 2012; 380: 1482–90. 570 
28. Räber L, Kelbæk H, Ostojic M, et al. Effect of biolimus-eluting stents with biodegradable polymer vs 571 
bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the 572 
COMFORTABLE AMI randomized trial. JAMA 2012; 308: 777–87. 573 
29. Sabaté M, Brugaletta S, Cequier A, et al. Clinical outcomes in patients with ST-segment elevation 574 
myocardial infarction treated with everolimus-eluting stents versus bare-metal stents 575 
(EXAMINATION): 5-year results of a randomised trial. Lancet 2016; 387: 357–66. 576 
Published in final edited form as: Lancet. 2019 Oct 5;394(10205):1243-1253. doi: 10.1016/S0140-6736(19)31877-X 
30. Räber L, Yamaji K, Kelbæk H, et al. Five-year clinical outcomes and intracoronary imaging findings 577 
of the COMFORTABLE AMI trial: randomized comparison of biodegradable polymer-based 578 
biolimus-eluting stents with bare-metal stents in patients with acute ST-segment elevation 579 
myocardial infarction. Eur Heart J 2019; 40: 1909–19. 580 
  581 
Published in final edited form as: Lancet. 2019 Oct 5;394(10205):1243-1253. doi: 10.1016/S0140-6736(19)31877-X 
TABLES 582 
Table 1: Baseline clinical characteristics 583 
  584 
Published in final edited form as: Lancet. 2019 Oct 5;394(10205):1243-1253. doi: 10.1016/S0140-6736(19)31877-X 
Table 2: Baseline angiographic and procedural characteristics 585 
 586 
Published in final edited form as: Lancet. 2019 Oct 5;394(10205):1243-1253. doi: 10.1016/S0140-6736(19)31877-X 
 587 
  588 
Published in final edited form as: Lancet. 2019 Oct 5;394(10205):1243-1253. doi: 10.1016/S0140-6736(19)31877-X 
Table 3: Clinical outcomes at 1 year 589 
 590 
  591 
Published in final edited form as: Lancet. 2019 Oct 5;394(10205):1243-1253. doi: 10.1016/S0140-6736(19)31877-X 
FIGURES 592 
Figure 1:  593 
Trial profile 594 
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Figure 2:  597 
Posterior distribution of the RR of the primary endpoint. 598 
Posterior distribution of the RR derived from Bayesian log Poisson models with robust priors 599 
incorporating data from the STEMI subgroup of the BIOSCIENCE trial. The solid red vertical line 600 
indicates the superiority margin. Dashed vertical lines indicate the lower and upper limits of the 95% 601 
Bayesian credibility interval. RR=rate ratio. 602 
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Figure 3:  606 
Time-to-event curves for target lesion failure (A), cardiac death (B), target vessel myocardial 607 
infarction (C), and clinically indicated target lesion revascularisation (D) in patients with ST-segment 608 
elevation myocardial infarction. 609 
RRs and CrIs estimated from Bayesian log Poisson models with robust priors incorporating data from 610 
the STEMI subgroup of the BIOSCIENCE trial. RR=rate ratio. CrI=Bayesian credibility interval. 611 
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Figure 4:  615 
Clinical outcomes at 1 year according to subgroups 616 
Bayesian posterior probability is the Bayesian posterior probability of RR<1·0 within each subgroup. 617 
The Bayesian posterior probability of the interaction is the Bayesian posterior probability of a 618 
difference between the two subgroups. RR=rate ratio. *Renal failure was defined as creatinine-619 
estimated glomerular filtration rate of less than 60 mL/min using the modification of diet in renal 620 
disease formula. †Small vessels were defined as stent diameter in any lesion ≤3·0 mm. ‡Long lesions 621 
were defined as total stent length in any lesion ≥20 mm. 622 
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